Pasithea Therapeutics Corp. (Nasdaq: KTTA), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders, today announced that Camac Partners, LLC, Camac Capital, LLC, Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Eric Shahinian, David Delaney, and Avi Geller (collectively, the “Camac Group”) satisfied the necessary requirements to call a Special Meeting of Stockholders.

The Company was notified that the Camac Group demonstrated the requisite votes on September 28, 2022, and notes that, contrary to their public statements, the Camac Group’s notifications prior to that date were invalid.

The Company stated, “During our first year as a public company, Pasithea has made significant progress towards our mandate to develop novel and groundbreaking drugs, including achieving positive preclinical results for our drug discovery programs, strengthening our team of scientists, expanding our portfolio with complementary CNS therapies with significant potential, and enhancing our recently reelected Board of Directors. We are excited about Pasithea’s future scientific and value creation prospects, and look forward to continued engagement with our stockholders.”

McDermott Will & Emery LLP are serving as legal advisor to the Company and Kingsdale Advisors is serving as an advisor in connection with the activities of the Camac Group.

About Pasithea Therapeutics Corp

Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.